How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibudilast.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ketas — Competitive Intelligence Brief

Ketas (IBUDILAST) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ibudilast. Area: Respiratory.

marketed ibudilast cAMP-specific 3',5'-cyclic phosphodiesterase 4A Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Ketas (IBUDILAST) — Kyorin Pharmaceutical.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketas TARGET	IBUDILAST	Kyorin Pharmaceutical	marketed	ibudilast	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1989-01-01
Leustatin	CLADRIBINE		marketed	Purine Antimetabolite [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1993-01-01
Otezla	Otezla	L.H. Kircik, M.D.	marketed		cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-11-23 — Leustatin · 10849919 · Method of Use · US
2041-09-10 — Leustatin · 12533408 · Method of Use · US
2041-09-10 — Leustatin · 12539329 · Method of Use · US

Sponsor landscape (ibudilast class)

Kyorin Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketas — Competitive Intelligence Brief. https://druglandscape.com/ci/ibudilast. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab